← Back to Search
Monoclonal Antibodies
YL217 for Cancer
San Antonio, TX
Phase 1
Waitlist Available
Research Sponsored by MediLink Therapeutics (Suzhou) Co., Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Aged ≥ 18 years
Histologically or cytologically confirmed diagnosis+ locally advanced unresectable or metastatic disease
Must not have
Undergone major surgery within 4 weeks before the first dose of study drug or expect major surgery during the study
Diagnosis or evidence of spinal cord compression or leptomeningeal carcinomatosis
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to approximately 3 years
Awards & highlights
No Placebo-Only Group
Summary
This trial is the first time YL217 is being tested in humans with advanced solid tumors.
See full description
Who is the study for?
Adults aged 18+ with advanced solid tumors, including certain gastrointestinal cancers, who can sign consent and follow study procedures. They must have at least one measurable tumor lesion, good organ function, and an ECOG performance status of 0 or 1. Those with HIV, recent major surgery, severe lung issues or specific prior treatments are excluded.Check my eligibility
What is being tested?
The trial is testing YL217, a new drug given as an intravenous infusion every three weeks to patients with various advanced solid tumors. It's the first time this drug is being tested in humans to see how safe it is and how well it works.See study design
What are the potential side effects?
As this is a first-in-human study for YL217, potential side effects are not yet fully known but may include typical reactions related to IV infusions such as pain at the injection site or allergic reactions.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am 18 years old or older.
show original
Select...
My cancer is advanced and cannot be removed by surgery.
show original
Select...
I am fully active or restricted in physically strenuous activity but can do light work.
show original
Select...
I have at least one tumor outside the brain that can be measured.
show original
Select...
I have a confirmed advanced solid tumor in my GI tract or related areas.
show original
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have not had major surgery in the last 4 weeks and do not expect any during the study.
show original
Select...
I have spinal cord compression or cancer spread to the lining of my brain.
show original
Select...
I have active tuberculosis.
show original
Select...
I am HIV positive.
show original
Select...
I stopped a specific cancer treatment due to side effects.
show original
Select...
I haven't taken steroids or immunosuppressants in the last 2 weeks.
show original
Select...
I haven't had a live vaccine in the last 4 weeks and won't get one during the study.
show original
Select...
I have severe lung problems due to another lung illness.
show original
Select...
I have been treated with a drug targeting CDH17 before.
show original
Select...
I have been treated with a specific type of chemotherapy.
show original
Select...
I haven't waited long enough after my last cancer treatment to start a new one.
show original
Select...
I do not have serious heart or brain blood vessel problems.
show original
Select...
I have or had lung inflammation not caused by infection, treated with steroids.
show original
Select...
I need frequent procedures to remove excess body fluids.
show original
Select...
I have a digestive condition that could lead to bleeding or blockage.
show original
Select...
I have an active hepatitis C infection.
show original
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to approximately 3 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to approximately 3 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Nature and frequency of adverse events (AEs) with severity
Nature and frequency of dose-limiting toxicity(DLT)
objective response rate (ORR)
Secondary study objectives
Characterize Pharmacokinetics(PK) parameter AUC
Characterize Pharmacokinetics(PK) parameter CL
Characterize Pharmacokinetics(PK) parameter Cmax
+12 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: The dose escalation stage, backfill stage and dose expansion stage of YL217Experimental Treatment1 Intervention
Part 1: The dose escalation stage:A preliminary anticipated dose-escalation sequence is 0.5, 1.0, 2.0, 3.0, and 4.0 mg/kg.
Part 2: Backfill stage:Patients will be enrolled at one or more dose levels that do not exceed the dose that is deemed safe and tolerable in dose escalation. Then at least two dose levels will be selected as the recommended dose for expansion (RDE).
Part 3: The dose expansion stage:Dose optimization will be performed in at least one of disease-specific cohorts where patients will be randomly assigned to two dose regimens in a 1:1 ratio.
Find a Location
Closest Location:Next Oncology· San Antonio, TX· 578 miles
Who is running the clinical trial?
MediLink Therapeutics (Suzhou) Co., Ltd.Lead Sponsor
11 Previous Clinical Trials
3,153 Total Patients Enrolled